RRoche Read More Roche’s OCREVUS Shows 30% Disability Reduction in Advanced PPMS Trial2026-02-17 Roche (OTCQX:RHHBY) presented new clinical data for OCREVUS and fenebrutinib at ECTRIMS 2025.…